Wednesday, October 19, 2011

VisionGate Raises $2M For Lung Cancer Detection

VisionGate, a developer of non-invasive tests for lung cancer, said today that it has raised $2M out of a $3M funding round. The firm, which has research and development offices in Seattle near the University of Washington, did not disclose the name of those investors. The firm is headquartered in Phoenix, Arizona. VisionGate develops a 3d cell imaging platform used to detect lung cancer earlier than existing methods. More information »